PHVS
Pharvaris BVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.80B
P/E Ratio
—
EPS
$-3.43
Beta
-2.58
52W High
$29.85
52W Low
$11.66
50-Day MA
$27.08
200-Day MA
$24.14
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pharvaris BV
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-169.63M |
| Operating Margin | 0.00% |
| Return on Equity | -65.20% |
| Return on Assets | -35.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.56 |
| Price-to-Book | 5.89 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $65.41M |
| Float | $35.06M |
| % Insiders | 5.20% |
| % Institutions | 90.68% |
Analyst Ratings
Consensus ($46.79 target)
3
Strong Buy8
Buy1
HoldData last updated: 4/9/2026